Phase II study of divided-dose vinblastine in advanced breast cancer patients.

Abstract

The pharmacokinetics of a 5-day, continuous infusion of vinblastine have been reproduced by an i.v. divided bolus at 0 and 48 h [10]; this schedule can be easily applied to outpatients. We treated 26 evaluable patients with refractory, advanced breast cancer with 3.5-4 mg/m2 vinblastine given i.v. by a divided bolus at 0 and 48 h of 21-day cycles. Neurotoxicity and myelosuppression were the main side effects: severe constipation and peripheral neurotoxicity developed in 14% and 3% of the patients, respectively; severe leukopenia and thrombocytopenia occurred in 24% and 10% of the patients, respectively. One partial response, 14 no changes, and 11 progressions were obtained. Our results do not support the use of vinblastine in divided doses in treating this disease.

• Authors: G Giaccone, M Bagatella, O Bertetto, M Donadio, A Calciati
• Journal: Cancer chemotherapy and pharmacology (Cancer Chemother Pharmacol) Vol. 21 Issue 1 Pg. 65-7 ( 1988) ISSN: 0344-5704 [Print] Germany
• PMID: 3342466 (Publication Type: Journal Article)

Chemical References

• Vinblastine

Topics

• Adult
• Aged
• Breast Neoplasms (drug therapy)
• Drug Administration Schedule
• Drug Evaluation
• Female
• Humans
• Middle Aged
• Vinblastine (administration & dosage, adverse effects)